Introduction
============

Skin cancer is one of the most frequent malignant diseases that arise from the skin in humans.[@b1-ott-10-3475] It is categorized into three main types: basal-cell skin cancer (BCC), squamous-cell skin cancer (SCC), and melanoma.[@b2-ott-10-3475] Non-melanoma skin cancer (NMSC) is the most commonly diagnosed cancer in white-skinned individuals with a worldwide increasing incidence.[@b3-ott-10-3475] It comprises BCC and SCC, as well as a host of rare tumors.[@b4-ott-10-3475] BCC and SCC together account for 95%--98% of all NMSC cases: the former is characterized by local invasiveness with rare metastasis; the latter has a higher metastatic potential and is responsible for the majority of deaths from NMSC.[@b5-ott-10-3475] The incidence of NMSC has been rising by 3%--8% per year since 1960, with as much as 300% increase in the past 2 decades.[@b6-ott-10-3475] Moreover, recent estimates demonstrate that more cases of NMSC have occurred in the past 30 years than all other forms of cancer combined.[@b7-ott-10-3475] The rising incidence rates of NMSC are probably caused by a combination of increased exposure to ultraviolet (UV) or sun light, ozone depletion, genetics, and immune suppression.[@b8-ott-10-3475] There are many approaches to the management of NMSC,[@b9-ott-10-3475] but the current treatment is limited due to low complete clearance rates.[@b10-ott-10-3475] In addition, treatment of NMSC is substantial and increasing, posing a considerable burden on the health care system.[@b11-ott-10-3475] Therefore, there is an urgent need to identify particular biomarkers that can predict this disease and guide the treatment options.

Various types of DNA damage could promote the development of human diseases.[@b12-ott-10-3475] DNA repair is a complicated biological process that maintains genome stability.[@b13-ott-10-3475] Epidemiologic research has found that genetic variants of DNA repair genes might be involved in cancer development.[@b14-ott-10-3475] X-ray repair cross-complementing group 1 (*XRCC1*) gene, located at chromosome 19q13.2, is a key component of base excision repair (BER) and is required for genetic stability.[@b15-ott-10-3475] It is required for repair in both DNA single-strand break repair and BER pathways and acts primarily as a scaffold protein that facilitates the assembly of multi-protein complexes and coordinating steps during damage.[@b16-ott-10-3475] XRCC1 is thought to play the repair role through protein--protein interactions or by direct contact with DNA.[@b17-ott-10-3475] Evidence has shown that polymorphisms in DNA repair genes could influence individual DNA repair capacity.[@b18-ott-10-3475] Genetic polymorphisms of *XRCC1* gene might contribute to impair DNA repair, thus playing a role in heightening the risk of NMSC. Three main single nucleotide polymorphisms (SNPs) in the coding region of *XRCC1* gene have been identified: amino acid substitution between arginine and glutamine at codon 399 (Arg399Gln, G to A base change, SNP number: rs25487) in exon 10, arginine and tryptophan at codon 194 (Arg194Trp, C to T base change, SNP number: rs1799782) in exon 6, and arginine and histidine at codon 280 (Arg280His, G to A base change, SNP number: rs25489) in exon 9. The 399Gln allele, located in the C-terminal functional domain, was shown to be associated with altering the phenotype of the XRCC1 protein;[@b19-ott-10-3475] the 194Trp variant, located in the linker region of the N-terminal functional domain, appeared to protect against genotoxic effects;[@b20-ott-10-3475] the 280His, located in the proliferating cell nuclear antigen-binding region, was suggested to impair and decrease DNA repair ability.[@b21-ott-10-3475] All these changes in conserved protein sites may alter the BER capacity and affect protein function, thus increasing the chances of DNA damage.[@b22-ott-10-3475],[@b23-ott-10-3475]

Although several studies have identified these three SNPs in the *XRCC1* gene and NMSC risk, the results still remain inconclusive. In addition, the incidence of NMSC varies widely worldwide based on geographical distribution with the highest rates in Australia and the lowest rates in parts of Africa.[@b24-ott-10-3475] Therefore, we conducted the present meta-analysis to systematically review all the published articles on this issue and to obtain a relatively reliable result.

Materials and methods
=====================

Search strategy
---------------

We searched the online databases of PubMed, Medline, Web of Science, and Embase to retrieve relevant articles published between January 2000 and November 2016. The Medical Subject Heading (MeSH) terms were "skin cancer or non-melanoma skin cancer", "basal-cell skin cancer or squamous-cell skin cancer", "DNA repair gene or X-ray repair cross-complementing group 1 or XRCC1", and "polymorphism or single nucleotide polymorphism or variant". We manually checked the references of retrieved articles to obtain more sources. Our study included articles written only in the English language. If the same authors had published more than one article on the same subject among the same participants, then only the most complete study was included in this meta-analysis.

Criteria for article screening
------------------------------

The articles that met the following criteria were included in the study: 1) case--control studies evaluating the relationship between XRCC1 polymorphisms and NMSC susceptibility, 2) studies in which NMSC was confirmed in patients by experienced pathologists, and controls were age-matched unrelated participants without any type of cancer, 3) studies in which the results were expressed as odds ratio (OR) with corresponding 95% confidence interval (CI), and 4) studies in which the genotype distribution of controls for a certain polymorphism was in Hardy--Weinberg Equilibrium (HWE). Studies whose data could not be extracted, those with duplicated data, and reviews or conference papers were excluded.

Qualification assessment and data extraction
--------------------------------------------

According to the Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement,[@b25-ott-10-3475] two authors independently estimated the quality of extracted articles. Any disagreement was resolved by discussing with the third author. Each item reached a final consensus. The following information was retrieved: the name of first author, publication year, country, ethnicity, mean age of patients and mean age of controls, total number of cases and controls, tumor types, and genotyping methods.

Statistical analyses
--------------------

Statistical analyses were carried out using Review Manager (Revman, version 5.3) software.[@b26-ott-10-3475] The association between XRCC1 polymorphisms and NMSC risk was evaluated by OR with 95% CI. The significance of the pooled OR was determined by *Z* test (*P*\<0.05 was considered significant). For each genetic variant, allelic model, homogeneous model, heterogeneous model, domain model, and recessive model were calculated. Cochran's *Q* test and *I*^2^ test were employed to evaluate the heterogeneity of the included articles;[@b27-ott-10-3475],[@b28-ott-10-3475] random-effect model was used when the *P*-value of Cochran's *Q* test was \<0.10 and *I*^2^ \>50%; otherwise, the fixed-effect model was used. To assess whether our results were substantially influenced by the presence of any individual study, we conducted a sensitivity analysis by systematically removing each study and recalculating the significance of the results. The funnel plot was performed to examine the publication bias.

Results
=======

Characteristics of eligible studies
-----------------------------------

We firstly identified 106 relevant articles. After applying the inclusion and exclusion criteria, a total of 10 articles were finally selected, including 6,683 participants (3,143 NMSC patients and 3,540 controls). [Figure 1](#f1-ott-10-3475){ref-type="fig"} shows the selection process of this meta-analysis. The 10 articles included were conducted in 10 different countries: UK,[@b29-ott-10-3475] Denmark,[@b30-ott-10-3475],[@b31-ott-10-3475] USA,[@b32-ott-10-3475] Sweden/Finland,[@b33-ott-10-3475] Sweden,[@b34-ott-10-3475] Korea,[@b35-ott-10-3475] Japan,[@b36-ott-10-3475] Germany,[@b37-ott-10-3475] and Taiwan (China).[@b38-ott-10-3475] Three were conducted in Asian populations and seven in Caucasian populations. The sample size ranged from 40 to 1,176. The genotypes of XRCC1 polymorphisms were determined using three methods. The genotype distributions of the controls of all studies were in agreement with HWE (*P*\>0.05). The main characteristics of the studies included are presented in [Table 1](#t1-ott-10-3475){ref-type="table"}.

Association between XRCC1 Arg399Gln polymorphism and NMSC susceptibility
------------------------------------------------------------------------

The summary of the test for association and test for heterogeneity of this meta-analysis is shown in [Table 2](#t2-ott-10-3475){ref-type="table"}. All these 10 articles concerned the effect of XRCC1 Arg399Gln polymorphism in NMSC risk, including 3,050 cases and 3,463 controls. No significant between-study heterogeneity was observed, and the fixed-effect model was employed. Our statistical analyses found that XRCC1 Arg399Gln polymorphism was not associated with increased risk of NMSC under the allelic model (Gln vs Arg: OR =0.97, 95% CI =0.90--1.05, *P*=0.42) as shown in [Figure 2](#f2-ott-10-3475){ref-type="fig"}. This insignificance was detected in other genetic models as well (Gln/Gln vs Arg/Arg: OR =0.90, 95% CI =0.77--1.06, *P*=0.20; Gln/Arg vs Arg/Arg: OR =1.02, 95% CI =0.92--1.14, *P*=0.69; Gln/Gln + Gln/Arg vs Arg/Arg: OR =0.99, 95% CI =0.90--1.10, *P*=0.89; Gln/Gln vs Gln/Arg + Arg/Arg: OR =0.90, 95% CI =0.77--1.04, *P*=0.16).

Subgroup analysis by ethnicities showed that only Gln/Arg genotype of this variant was significantly correlated with increased risk of NMSC under the heterogeneous model in Asian populations (Gln/Arg vs Arg/Arg: OR =1.39, 95% CI =1.04--1.87, *P*=0.03) as shown in [Figure 3](#f3-ott-10-3475){ref-type="fig"}. This positive relationship was not found in other genetic models. Moreover, no significant relationship was found between XRCC1 Arg399Gln variant and NMSC risk under any genetic models in Caucasian populations (*P*\>0.05). Subgroup analysis by NMSC types showed that XRCC1 Arg399Gln variant was not associated with NMSC risk in both BCC and SCC types.

Association between XRCC1 Arg194Trp polymorphism and NMSC susceptibility
------------------------------------------------------------------------

Four articles focused on this genetic variant, containing 914 cases and 1,182 controls. The frequency of Trp allele was a little higher in the patient group than that in the control group (14.6% vs 12.6%), but statistical analyses did not detect significant association between XRCC1 Arg194Trp variant and NMSC risk under the five genetic models as shown in [Table 2](#t2-ott-10-3475){ref-type="table"}. Subgroup analysis by ethnicities showed that XRCC1 Arg194-Trp polymorphism was not associated with NMSC risk among Asian and Caucasian populations (*P*\>0.05). Subgroup analysis by NMSC types showed that Trp/Trp genotype was positively associated with decreased cancer risk in SCC type under the homogeneous model (Trp/Trp vs Arg/Arg: OR =0.38, 95% CI =0.16--0.92, *P*=0.03) as shown in [Figure 4](#f4-ott-10-3475){ref-type="fig"}. However, this correlation was not found in patients with BCC type.

Association between XRCC1 Arg280His polymorphism and NMSC susceptibility
------------------------------------------------------------------------

Two articles included 279 cases and 413 controls. Our results showed that XRCC1 Arg280His polymorphism was not associated with NMSC risk under each genetic model (His vs Arg: OR =0.88, 95% CI =0.38--2.05, *P*=0.78; His/His vs Arg/Arg: OR =0.87, 95% CI =0.21--3.50, *P*=0.84; His/Arg vs Arg/Arg: OR =0.97, 95% CI =0.48--1.95, *P*=0.93; His/His + His/Arg vs Arg/Arg: OR =0.92, 95% CI =0.41--2.07, *P*=0.84; His/His vs His/Arg + Arg/Arg: OR =0.87, 95% CI =0.21--3.53, *P*=0.84).

Sensitivity analysis and publication bias
-----------------------------------------

We systematically omitted each single article one at a time to verify whether our results were influenced by each included study. Our results showed that the pooled ORs were not significantly changed. The funnel plot was used to assess the publication bias of the literature. All genetic comparisons in our study showed no evidence of publication bias as shown in [Figure 5](#f5-ott-10-3475){ref-type="fig"}, which indicates that there was no publication bias in the present meta-analysis.

Discussion
==========

In this meta-analysis, we screened 10 relevant articles in total. We found that Arg399Gln, Arg194Trp, and Arg280His polymorphisms of the *XRCC1* gene were not associated with NMSC risk in the total studied populations. However, subgroup analysis showed that only Gln/Arg genotype of XRCC1 Arg399Gln variant was significantly correlated with increased risk of NMSC in Asian populations, and Trp/Trp genotype of XRCC1 Arg194Trp variant was positively associated with decreased risk of SCC type. Our results were not consistent with the previous meta-analysis, which studied the association between polymorphisms of the *XRCC1* gene and skin cancer risk, and showed that no significant association was observed in stratified analyses of Arg399Gln and Arg194Trp polymorphisms and tumor type (SCC, BCC, and melanoma).[@b39-ott-10-3475]

Harmful effects of solar UV radiation on human health is one of the causes of NMSC.[@b40-ott-10-3475] Exposure to UV radiation initiates \~90% of NMSC, causing malignant transformation of keratinocytes and suppression of inflammatory response. A reduced capacity to repair UV-induced DNA damage is one of the underlying molecular mechanisms for sunlight-induced skin carcinogenesis in the general population.[@b41-ott-10-3475] Evidence showed that a low DNA repair capacity was a susceptibility factor for NMSC.[@b42-ott-10-3475]--[@b44-ott-10-3475] The XRCC1 protein, involved in the DNA repair pathway, is essential for the maintenance of genomic stability.[@b45-ott-10-3475] It serves to orchestrate BER via its role as a central scaffolding protein physically associated with DNA ligase III and via its function in recognizing and binding to single-strand breaks.[@b46-ott-10-3475],[@b47-ott-10-3475] XRCC1 is also involved in the organization of BER into multi-protein complexes of different sizes to DNA damage sites,[@b48-ott-10-3475] and defects in BER are shown to be linked with immunodeficiency, neurodegenerative disorders, and cancer predisposition.[@b49-ott-10-3475]

Some studies have shown that polymorphisms in DNA repair genes might change the risk of cancer development.[@b50-ott-10-3475]--[@b52-ott-10-3475] Variant genotypes of *XRCC1* gene that cause amino acid substitutions may affect protein structure and gene expression, and impair the interaction of XRCC1 with the other enzymatic proteins, thus altering the BER function. For example, XRCC1 polymorphisms could influence cell responses to X-rays, and Arg399Gln of XRCC1 was shown to be associated with higher levels of DNA breaks;[@b53-ott-10-3475] the polymorphic variant Arg280His exhibited a slightly shorter retention time at DNA breaks.[@b54-ott-10-3475] XRCC1 polymorphisms might be associated with human cancer and could function as biomarkers of cancer susceptibility: Arg399Gln polymorphism was associated with lung cancer[@b55-ott-10-3475] and breast cancer;[@b56-ott-10-3475] Arg194Trp polymorphism was found to be associated with gastric cancer[@b57-ott-10-3475] and breast cancer;[@b58-ott-10-3475] and Arg280His was associated with invasive cervical cancer[@b59-ott-10-3475] and pancreatic cancer.[@b60-ott-10-3475] A previous review showed that the homozygous variant (Gln/Gln) of Arg399Gln variant can have 3--4-fold diminished capacity to remove DNA adducts and oxidized DNA damage; Arg280His variant appeared to decrease repair function, but Arg194Trp variant appears to protect against genotoxic effects.[@b20-ott-10-3475] This was consistent with our result. Several studies have identified the role of XRCC1 variants in skin cancer risk. Previous meta-analysis suggested that XRCC1 Arg399Gln polymorphism was a risk factor for cutaneous melanoma in a population-based subgroup.[@b61-ott-10-3475] Only the 10 studies included in the present meta-analysis analysed the effect of XRCC1 polymorphism in NMSC risk. For instance, a study that included \~300 Koreans showed that Arg/Gln and Gln/Gln genotypes had an \~2-fold increased risk of BCC compared to Arg/Arg individuals,[@b35-ott-10-3475] whereas another study that included \~1,000 Caucasians showed that Arg/Arg genotype had significantly reduced risk of both BCC and SCC.[@b29-ott-10-3475] In addition, genes of DNA BER pathway might be evolving as biomarkers for personalized therapies in cancer.[@b62-ott-10-3475] Polymorphisms in DNA repair genes might exert a role in survival, might facilitate response to chemotherapy, and might predict prognosis. Figl et al showed that variants in potential regulatory regions of DNA repair genes might influence disease outcome in melanoma patients and have potentially significant implications for patient surveillance and tailored treatment.[@b63-ott-10-3475] XRCC1 risk allele may result in resistance to therapy and shorter survival in bladder cancer patients treated with chemotherapy.[@b64-ott-10-3475] XRCC1 Gln allele genotype showed significant prognostic associations in hepatocellular carcinoma.[@b65-ott-10-3475] Bhandaru et al demonstrated that loss of XRCC1 expression was correlated with the progression of melanoma from dysplastic nevi to primary melanoma and to metastatic melanoma, and with worse overall and disease-specific 5-year and 10-year survival of patients with melanoma.[@b66-ott-10-3475]

Several limitations were presented in this meta-analysis. 1) The included studies were conducted only in Asian and Caucasian populations, and other ethnicities were not considered. 2) The number of included studies for a certain SNP such as Arg280His variants was small, which may result in possible bias related to the selection of individual study participants. 3) Other risk factors such as age and gender should be analyzed. 4) The interaction of gene--gene and gene--environment should be included in future research because the combined effect of multiple SNPs in several genes of DNA repair pathways could have a large impact on pathological phenotypes.

Conclusion
==========

Our results found that Arg399Gln polymorphism of *XRCC1* gene might be a risk factor for NMSC in Asian populations and Arg194Trp variant of *XRCC1* gene might be a protective factor for SCC patients. However, future large-scale, well-designed studies with more ethnicities are still needed to further investigate the role of XRCC1 polymorphisms in NMSC risk.
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###### 

The detailed characteristics of all studies included in this meta-analysis

  Author                               Year   Country (ethnicity)           Mean age (years)   Sample size   Tumor types   Genotyping method   HWE in controls                
  ------------------------------------ ------ ----------------------------- ------------------ ------------- ------------- ------------------- ----------------- ------------ -------
  Nelson et al[@b29-ott-10-3475]       2002   UK (Caucasians)               --                 --            745           431                 BCC + SCC         PCR-RFLP     0.185
  Yin et al[@b30-ott-10-3475]          2002   Denmark (Caucasians)          20--60             20--60        63            97                  BCC               SNaPshot     0.774
  Yin et al[@b31-ott-10-3475]          2003   Denmark (Caucasians)          \<50               \<50          20            20                  BCC               PCR-RFLP     0.983
  Han et al[@b32-ott-10-3475]          2005   USA (Caucasians)              64.7               64.5          586           874                 BCC + SCC         Sequencing   0.161
  Festa et al[@b33-ott-10-3475]        2005   Sweden/Finland (Caucasians)   --                 --            197           548                 BCC               PCR-RFLP     0.973
  Thirumaran et al[@b34-ott-10-3475]   2006   Sweden (Caucasians)           63.5±11.7          60.0±11.8     529           533                 BCC               Sequencing   0.838
  Kang et al[@b35-ott-10-3475]         2007   Korea (Asian)                 68.98±12.6         46.42±16.6    212           207                 BCC + SCC         PCR-RFLP     0.673
  Chiyomaru et al[@b36-ott-10-3475]    2012   Japan (Asian)                 72.9±12.2          66.1±13.7     103           93                  BD + BCC + SCC    PCR-RFLP     0.097
  Surdu et al[@b37-ott-10-3475]        2014   Germany (Caucasians)          30--79             30--79        618           527                 BCC + SCC         Sequencing   0.838
  Hsu et al[@b38-ott-10-3475]          2015   China Taiwan (Asian)          56.13±6.87         54.38±6.26    70            210                 BCC + SCC + BD    PCR-RFLP     0.156

**Note:** The data are presented as mean values ± standard deviation.

**Abbreviations:** --, not available; BCC, basal-cell skin cancer; SCC, squamous-cell skin cancer; BD, Bowen's diseases; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; HWE, Hardy--Weinberg equilibrium.

###### 

Meta-analysis and stratified analyses of Arg399Gln, Arg194Trp, and Arg280His in the coding region of *XRCC1* gene with NMSC risk under each genetic model

  SNPs                           Group               N            Comparisons         Test of association   Test of heterogeneity                 
  ------------------------------ ------------------- ------------ ------------------- --------------------- ----------------------- ------ ------ ---
  **Arg399Gln**                                      10           Gln vs Arg          0.97 (0.90--1.05)     0.42                    26     0.21   F
  Gln/Gln vs Arg/Arg             0.90 (0.77--1.06)   0.20         22                  0.24                  F                                     
  Gln/Arg vs Arg/Arg             1.02 (0.92--1.14)   0.69         0                   0.46                  F                                     
  Gln/Gln + Gln/Arg vs Arg/Arg   0.99 (0.90--1.10)   0.89         5                   0.40                  F                                     
  Gln/Gln vs Gln/Arg + Arg/Arg   0.90 (0.77--1.04)   0.16         28                  0.18                  F                                     
  Asian                          3                   Gln vs Arg   1.04 (0.70--1.55)   0.85                  70                      0.04   R      
  Gln/Gln vs Arg/Arg             0.94 (0.43--2.05)   0.88         61                  0.07                  R                                     
  Gln/Arg vs Arg/Arg             1.39 (1.04--1.87)   0.03         0                   0.70                  F                                     
  Gln/Gln + Gln/Arg vs Arg/Arg   1.26 (0.96--1.66)   0.10         38                  0.20                  F                                     
  Gln/Gln vs Gln/Arg + Arg/Arg   0.83 (0.41--1.70)   0.61         57                  0.10                  R                                     
  Caucasians                     7                   Gln vs Arg   0.95 (0.88--1.03)   0.24                  0                       0.67   F      
  Gln/Gln vs Arg/Arg             0.90 (0.76--1.07)   0.22         5                   0.39                  F                                     
  Gln/Arg vs Arg/Arg             0.98 (0.87--1.09)   0.67         0                   0.78                  F                                     
  Gln/Gln + Gln/Arg vs Arg/Arg   0.96 (0.86--1.07)   0.42         0                   0.82                  F                                     
  Gln/Gln vs Gln/Arg + Arg/Arg   0.91 (0.77--1.06)   0.23         23                  0.25                  F                                     
  BCC                            9                   Gln vs Arg   0.97 (0.90--1.06)   0.51                  40                      0.10   F      
  Gln/Gln vs Arg/Arg             0.89 (0.74--1.06)   0.20         2                   0.42                  F                                     
  Gln/Arg vs Arg/Arg             1.04 (0.92--1.17)   0.52         45                  0.07                  F                                     
  Gln/Gln + Gln/Arg vs Arg/Arg   1.00 (0.90--1.12)   0.94         46                  0.06                  F                                     
  Gln/Gln vs Gln/Arg + Arg/Arg   0.89 (0.72--1.09)   0.24         20                  0.27                  F                                     
  SCC                            5                   Gln vs Arg   0.99 (0.78--1.25)   0.92                  63                      0.03   R      
  Gln/Gln vs Arg/Arg             0.99 (0.56--1.76)   0.98         71                  0.008                 R                                     
  Gln/Arg vs Arg/Arg             0.99 (0.82--1.19)   0.88         0                   0.58                  F                                     
  Gln/Gln + Gln/Arg vs Arg/Arg   0.95 (0.80--1.13)   0.57         19                  0.30                  F                                     
  Gln/Gln vs Gln/Arg + Arg/Arg   0.97 (0.57--1.64)   0.90         70                  0.01                  R                                     
  **Arg194Trp**                                      4            Trp vs Arg          0.98 (0.82--1.19)     0.86                    46     0.13   F
  Trp/Trp vs Arg/Arg             0.72 (0.43--1.22)   0.22         0                   0.88                  F                                     
  Trp/Arg vs Arg/Arg             1.10 (0.72--1.70)   0.65         60                  0.06                  R                                     
  Trp/Trp + Trp/Arg vs Arg/Arg   1.03 (0.69--1.54)   0.87         58                  0.07                  R                                     
  Trp/Trp vs Trp/Arg + Arg/Arg   0.72 (0.44--1.20)   0.21         0                   0.97                  F                                     
  Asian                          2                   Trp vs Arg   0.91 (0.61--1.36)   0.64                  58                      0.12   R      
  Trp/Trp vs Arg/Arg             0.74 (0.41--1.31)   0.30         0                   0.53                  F                                     
  Trp/Arg vs Arg/Arg             1.06 (0.45--2.51)   0.90         82                  0.02                  R                                     
  Trp/Trp + Trp/Arg vs Arg/Arg   0.97 (0.47--2.01)   0.94         78                  0.03                  R                                     
  Trp/Trp vs Trp/Arg + Arg/Arg   0.74 (0.43--1.29)   0.29         0                   0.98                  F                                     
  Caucasians                     2                   Trp vs Arg   1.17 (0.87--1.56)   0.30                  0                       0.34   F      
  Trp/Trp vs Arg/Arg             0.66 (0.18--2.35)   0.52         0                   0.62                  F                                     
  Trp/Arg vs Arg/Arg             1.27 (0.92--1.74)   0.14         0                   0.73                  F                                     
  Trp/Trp + Trp/Arg vs Arg/Arg   1.22 (0.90--1.67)   0.20         0                   0.50                  F                                     
  Trp/Trp vs Trp/Arg + Arg/Arg   0.64 (0.18--2.29)   0.50         0                   0.64                  F                                     
  BCC                            4                   Trp vs Arg   1.02 (0.81--1.29)   0.84                  0                       0.59   F      
  Trp/Trp vs Arg/Arg             0.97 (0.53--1.77)   0.92         0                   0.80                  F                                     
  Trp/Arg vs Arg/Arg             1.06 (0.80--1.41)   0.68         0                   0.49                  F                                     
  Trp/Trp + Trp/Arg vs Arg/Arg   1.05 (0.80--1.38)   0.73         0                   0.53                  F                                     
  Trp/Trp vs Trp/Arg + Arg/Arg   1.25 (0.70--2.25)   0.46         0                   0.74                  F                                     
  SCC                            3                   Trp vs Arg   0.91 (0.55--1.51)   0.71                  73                      0.03   R      
  Trp/Trp vs Arg/Arg             0.38 (0.16--0.92)   0.03         0                   0.90                  F                                     
  Trp/Arg vs Arg/Arg             1.11 (0.52--2.38)   0.78         82                  0.004                 R                                     
  Trp/Trp + Trp/Arg vs Arg/Arg   0.99 (0.49--2.00)   0.98         80                  0.007                 R                                     
  Trp/Trp vs Trp/Arg + Arg/Arg   0.42 (0.18--1.00)   0.05         0                                         F                                     
  **Arg280His**                                      2            His vs Arg          0.88 (0.38--2.05)     0.78                    74     0.05   R
  His/His vs Arg/Arg             0.87 (0.21--3.50)   0.84         0                   0.34                  F                                     
  His/Arg vs Arg/Arg             0.97 (0.48--1.95)   0.93         58                  0.12                  R                                     
  His/His + His/Arg vs Arg/Arg   0.92 (0.41--2.07)   0.84         69                  0.07                  R                                     
  His/His vs His/Arg + Arg/Arg   0.87 (0.21--3.53)   0.84         0                   0.38                  F                                     

**Abbreviations:** NMSC, non-melanoma skin cancer; SNP, single nucleotide polymorphism; N, number of included studies; OR, odds ratio; CI, confidence interval; F, fixed-effect model; R, random-effect model; BCC, basal-cell skin cancer; SCC, squamous-cell skin cancer; Ph, *P*-value of heterogeneity.
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